In late March 2026, Imexpharm Pharmaceutical JSC partnered with two major scientific conferences specializing in Respiratory and ENT (Ear, Nose, and Throat) medicine in Vung Tau and Nha Trang. This activity underscores the company’s strategy to bridge the gap between laboratory research and real-world clinical application.
Key highlights from the events:
-
Pioneering Specialized Medicine: The company currently operates 12 EU-GMP certified production lines, focusing on next-generation antibiotics and treatments for severe infections. Notably, the production of aerosol-based active ingredients provides vital support for hospitals in managing drug-resistant cases.
-
Investment in R&D and Green Manufacturing: Allocating 5% of its annual revenue to Research and Development, the firm maintains over 100 projects per year. The production process utilizes Enzymatic technology to minimize chemical solvents, ensuring product purity and alignment with international ESG (Environmental, Social, and Governance) standards.
-
Addressing Public Health Challenges: Amidst rising air pollution and climate change increasing the respiratory disease burden in Vietnam, the company focuses on supplying high-quality generic drugs at reasonable costs, facilitating broader access to advanced therapies.
-
Commitment to Sustainable Development: Beyond professional activities, the firm implements environmental improvement projects, such as tree-planting initiatives in Da Lat, to promote respiratory health by protecting the living environment.
The participation of pharmaceutical enterprises in specialized scientific forums is considered a crucial factor in integrating advancements in Artificial Intelligence and immunology into the primary healthcare system.
Source: https://vnexpress.net/imexpharm-dong-hanh-hai-hoi-nghi-chuyen-nganh-ho-hap-5055364.html